CENTRAL TRUST Co Sells 85,365 Shares of Pfizer Inc. $PFE

Key Points

• CENTRAL TRUST Co cut its Pfizer stake by 21.3%, selling 85,365 shares and now holds 314,488 shares valued at about $7.83 million.
• Pfizer beat Q4 estimates (EPS $0.66 vs $0.57; revenue $17.56B vs $16.93B) and announced a quarterly dividend of $0.43 (annualized yield ~6.5%) while reporting a payout ratio of 126%.
• Positive pipeline and regulatory news — including FDA approval for a Pfizer–Arvinas breast cancer therapy, Vyndamax patent settlements extending exclusivity to 2031, and a late‑stage win for Elrexfio — could bolster medium‑term revenue outlook.

CENTRAL TRUST Co lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 314,488 shares of the biopharmaceutical company's stock after selling 85,365 shares during the period. CENTRAL TRUST Co's holdings in Pfizer were worth $7,831,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Franklin Resources Inc. boosted its holdings in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after purchasing an additional 6,045,763 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after purchasing an additional 5,978,927 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Pfizer by 120.9% during the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 1.3%

Shares of NYSE PFE opened at $26.35 on Friday. The firm's 50-day moving average price is $27.17 and its 200-day moving average price is $26.10. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $149.80 billion, a price-to-earnings ratio of 19.37 and a beta of 0.35. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the company posted $0.63 EPS. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is 126.47%.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. BMO Capital Markets restated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.74.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA approval for a Pfizer–Arvinas breast cancer therapy — The U.S. FDA approved the co‑developed drug for a breast cancer indication, giving Pfizer an additional commercial launch and validating its oncology partnership pipeline. This approval creates a new near‑ and medium‑term revenue opportunity and reduces development risk for the asset. US FDA approves Pfizer, Arvinas' breast cancer drug
• Positive Sentiment: Vyndamax patent settlements extend exclusivity to 2031 — Pfizer reached settlements with multiple generic filers that effectively push back generic entry for Vyndamax (tafamidis), protecting a meaningful revenue stream and reducing downside risk from near‑term generic competition. That supports cash flow visibility into the next decade. Pfizer Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
• Positive Sentiment: Late‑stage win for multiple myeloma drug Elrexfio — Pfizer reported a late‑stage trial success for Elrexfio, which could expand its oncology franchise and add future revenue streams if regulatory filings follow. Clinical wins can meaningfully re‑rate biotech exposure over time. Pfizer posts late-stage trial win for multiple myeloma therapy Elrexfio
• Positive Sentiment: PADCEV supplemental BLA accepted for priority review — Pfizer (with Astellas) secured FDA acceptance of a PADCEV sBLA for a new use, which could expand indications and sales if approved. This is another program that supports medium‑term growth optionality. Pfizer Among Best Medical Stocks Under $30 to Invest In?
• Neutral Sentiment: Q1 earnings and guidance in focus (May 5) — Wall Street is watching first‑quarter results and guidance; Zacks and other outlets highlight consensus estimates and key revenue/margin line items, with traders positioning ahead of potential beats and for commentary on obesity and specialty drug performance. Earnings will likely be the short‑term catalyst for direction. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings
• Negative Sentiment: Analyst caution and price‑target cuts are weighing on sentiment — Goldman reportedly trimmed its target and some sell‑side commentary highlights growth concerns despite the patent wins; Morgan Stanley reiterated Equal Weight and flagged patent/growth uncertainty. That cautious analyst tone can sap momentum and contribute to intraday selling. Pfizer Stock Opinions on Vyndamax Settlements and Earnings Outlook Morgan Stanley Maintains Pfizer at Equal Weight

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.